Singota Solutions
Singota Solutions is a private Bloomington, Indiana-based contract drug development firm founded in 2006 that provides formulation development, analytical testing, aseptic manufacturing, and labeling services to pharmaceutical clients.
- Company typePrivate
- Founded2006
- HeadquartersBloomington, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Singota Solutions does
Singota Solutions is a private, U.S.-based contract drug development firm headquartered in Bloomington, Indiana, founded in 2006 by Alisa Kilgas, who continues to serve as Founder & CEO. The company operates in the contract development and manufacturing organization (CDMO) segment of the pharmaceutical services value chain, providing four integrated service lines: formulation development, analytical testing, aseptic manufacturing, and labeling. These capabilities position Singota to support drug developers — particularly those working on parenteral/injectable products requiring sterile fill-finish — across preclinical through clinical and small-scale commercial stages. With a headcount of 101–250 employees, the firm sits in the mid-size tier of U.S. CDMOs and is differentiated from larger peers by its regional, single-site footprint rather than by a global network of facilities.
The business model is service-based, typical of small-to-mid CDMOs: revenue is generated through project- and program-based contracts for formulation work, method development and validation, GMP analytical testing, aseptic fill-finish batches, and labeling/packaging activities. Customer relationships are likely structured around multi-phase programs with milestone or unit-based pricing rather than subscription or platform licensing models. The company's Bloomington location — outside the traditional Boston/New Jersey/Research Triangle CDMO corridors — suggests a regional commercial focus, though the source data does not disclose specific customer segments, named clients, geographic markets served, or pricing structure. No revenue, funding, ownership, or financial details were available in the provided sources, and the company website was inaccessible at time of data collection.
Strategically, the source material is thin on recent moves: no funding rounds, acquisitions, partnerships, leadership changes, product launches, regulatory milestones, or expansion announcements are documented. The single verifiable strategic action is the company's 2006 founding. Intangible assets (specialized sterile and analytical capabilities) and regulatory credentials from 18 years of GMP operations constitute the most defensible moat dimensions, while AI/ML capability is not evidenced in the data. Overall, the analytical picture is that of an established, founder-led mid-size CDMO with limited public information available for deeper investment scrutiny.
Singota Solutions firmographics
Firmographics- Name
- Singota Solutions
- Website
- https://singota.com
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 51–100 employees
- Short description
- Singota Solutions is a private Bloomington, Indiana-based contract drug development firm founded in 2006 that provides formulation development, analytical testing, aseptic manufacturing, and labeling services to pharmaceutical clients.
- Ownership category
- akta.pro rank
Singota Solutions industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)
- akta.pro secondary industries
- Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), Method Development & Validation (ICH/USP) (HLAGADAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)
Keywords
Where Singota Solutions is headquartered
LocationHeadquarters
- HQ city
- Bloomington
- HQ country
- United States
- HQ region
- North America
Markets served
Singota Solutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Singota Solutions product offering
Product offeringCore offering
Singota Solutions is a contract drug development and manufacturing organization offering formulation development, analytical testing, aseptic making (sterile fill-finish), and labeling services for pharmaceutical and biotech clients. The firm supports drug product development from pre-clinical through clinical stages at its Bloomington, Indiana facility.
Differentiator
Problem solved
Functional benefit
Products and services
- Formulation Development Drug product formulation development services supporting pharmaceutical and biotech clients in developing sterile and parenteral dosage forms. Provided to drug developers requiring outsourced formulation expertise.
- Analytical Testing Analytical testing services to support drug development and manufacturing release, providing quality and characterization data for pharmaceutical and biotech clients.
- Aseptic Making (Aseptic Fill-Finish) Sterile aseptic fill-finish manufacturing services for injectable and parenteral drug products, supporting clinical and small-scale commercial supply for pharmaceutical and biotech sponsors.
- Labeling Services Pharmaceutical labeling services providing clinical and commercial labeling of drug product units prepared through Singota's formulation and aseptic manufacturing workflows.
Companies that use Singota Solutions
Customer profileIdeal customer profiles1 record
Singota Solutions technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Singota Solutions partnerships and signals
Strategic signalRecent moves1 record
Singota Solutions competitors and assessment
Company assessmentEmerging players
- Ardena: Specialty CDMO focused on formulation development, analytical services, and clinical supply for small-to-mid pharma and biotech — closely mirrors Singota's early-phase service mix and customer profile at similar scale.
Broad incumbents
- Aenova Group: European CDMO with sterile and aseptic manufacturing capabilities serving pharma and consumer health — comparable in development-through-commercial service stack to Singota, though with different geographic focus.
- Recipharm: European-headquartered CDMO offering sterile fill-finish, formulation development, and analytical services across small molecules and biologics — competes with Singota for injectable and clinical supply programs.
- Thermo Fisher Scientific (Patheon): Through its Patheon CDMO business, Thermo Fisher offers end-to-end pharmaceutical development and sterile manufacturing at global scale — overlapping with Singota's formulation, analytical, and aseptic fill services.
- Vetter Pharma: Germany-based specialist in aseptic fill-finish of injectable drugs, including complex biologics and ophthalmics — a benchmark for sterile injectable CDMO capability that competes for the same clinical and commercial sponsors.
- Catalent: Global large-molecule and small-molecule CDMO with significant clinical and commercial sterile fill-finish capacity across biologics and injectables — sets the competitive benchmark Singota is benchmarked against on flexibility and turnaround.
- PCI Pharma Services: Global CDMO with strong sterile fill-finish, lyophilization, and clinical supply services; absorbed LSNE in 2021. Competes with Singota across clinical-stage injectable manufacturing and packaging.
Direct peers
- Alcami Corporation: US-based mid-sized CDMO offering sterile fill-finish, analytical development, and formulation services to small and mid-cap pharma — directly comparable scale and service mix to Singota.
- Symbiosis Pharmaceutical Services: UK-based specialist CDMO focused on aseptic vial filling and lyophilization for clinical trials. Highly comparable in service scope (clinical sterile fill-finish) though geographically focused on European sponsors.
- LSNE (Lyophilization Services of New England): Specialty CDMO historically focused on aseptic fill-finish and lyophilization for clinical-stage injectables and biologics — the closest comparable to Singota in modality, batch size, and customer segment. Now operates within PCI Pharma Services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Singota Solutions social profiles
Digital presenceSingota Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Singota Solutions leadership team
Management profileNumber of profiles
Profiles1 record
Singota Solutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Singota Solutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Singota Solutions
What does Singota Solutions do?
Singota Solutions is a contract drug development and manufacturing organization offering formulation development, analytical testing, aseptic making (sterile fill-finish), and labeling services for pharmaceutical and biotech clients. The firm supports drug product development from pre-clinical through clinical stages at its Bloomington, Indiana facility.
When was Singota Solutions founded?
Singota Solutions was founded in 2006. It employs 51 to 100 people.
Where is Singota Solutions based?
Singota Solutions is headquartered in Bloomington, United States, in the North America region.
Who are Singota Solutions's main competitors?
Ardena is listed as an emerging player. Broad incumbents are Aenova Group, Recipharm, Thermo Fisher Scientific (Patheon), Vetter Pharma, Catalent and PCI Pharma Services. Direct peers are Alcami Corporation, Symbiosis Pharmaceutical Services and LSNE (Lyophilization Services of New England).
Does Singota Solutions have an API?
No public API is recorded for Singota Solutions.
What industry is Singota Solutions in?
Singota Solutions's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services, with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 325412 and its SIC code is 8731.